Developping Strategic Partnerships

ReadyCell counts on a wide range of strategic partners with which the company has developed strong and long-lasting strategic partnerships. This consists in collaboration, joint initiatives, common projects and more.

ADMEcell develops, manufactures and distributes Ready-to-Use products for in vitro therapeutic modeling and re-profiling. ADMECell provides products whose technology is relevant in the evolving and complex environment of ADME/Toxicology. Their products help you focus your resources on discovery and development, increasing your chances of success.
SOLVO is a codeveloper of PreadyPort™ kits. SOLVO develops transporter assays, based on the latest results in transporter science, the needs of the pharmaceutical industry and the guidelines for drug drug interaction studies by the FDA and EMA. With 17 years of experience and 500 customers in 40 countries, SOLVO Biotechnology is the leading provider of transporter services and products. Leveraging our expertise in efflux and uptake transporters, SOLVO generates quality reports for submission to FDA/EMA. From small molecules to protein therapeutics, SOLVO can test all your transporter needs.
Kirklees Biosciences is an independent biotechnology company providing high quality bio-products and services whilst also developing a unique R&D portfolio. Kirklees Biosciences supply innovative, high quality bio-products, reagents and cell based ready to use kits for use in progressing drug discovery & development programmes. Kirklees research initiatives utilise key commercial partnerships and academic collaborations to facilitate the development and discovery of novel therapies.
Genomembrane is a Japanase biotech company that has the aim to provie transporter- related products and services for the development and design of novel drugs for clinical application. Genomembrane also provides research tools and collaborates for the pharmaceutical evaluation of drug candidates in order to lessen cost and help advance the success rate of candidate drug, and speed up new drug development.

Leitat is a private technical institute with more than 110 years of experience in industrial innovation processes. It transforms technological and scientific results into economic and competitive value for its clients and collaborating entities. Over 1500 customers benefit from its talent, creativity and strong commitment. It brings knowledge and innovation to its customers through applied research and technical testing in the fields of chemistry, energy, environment, materials, engineering and life sciences. It relies upon its 240 highly skilled team members who deliver flexible solutions to face any industrial challenge.

IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer)is a centre for research of excellence that tackles high-prevalence, high-morbidity and high-mortality diseases. Founded in 1996, it is a public consortium whose members are the Catalan Government, the Hospital Clínic of Barcelona, the University of Barcelona’s School of Medicine and the CSIC Biomedical Research Institute in Barcelona.

ACCIÓ is the public agency for the competitiveness of the Catalan government. Its objective is to boost the competitiveness and growth of the Catalan businesses through the promotion of innovation, business internationalization and the attraction of investments. It is responsible for attracting foreign investments to Catalonia, a task that is carried out through the Catalonia Trade & Investment area, which is specifically responsible for promoting Catalonia as an attractive, innovative and competitive area for foreign companies. The agency accompanies and advises foreign companies during all phases of their projects, when looking for partners, the most competitive suppliers or the technology they need to establish in Catalonia. Currently, ACCIÓ accounts with a network of 40 foreign  offices worldwide and seven branches throughout Catalonia. It collaborates with local and international business entities to add synergies and ensure that the Catalan company has a broader range of tools to grow in competitiveness.

The Netherlands Cancer Institute was established on October 10, 1913. The founders wanted to create a cancer institute ‘where patients suffering from malignant growths could be treated adequately and where cancer and related diseases could be studied’. Nowadays, The Netherlands Cancer Institute accommodates approximately 650 scientists and scientific support personnel. The Antoni van Leeuwenhoek Hospital has 185 medical specialists, 180 beds, an out-patients clinic with around 106,000 visits, 12 operating theaters and 11 irradiotion units for radiotherapy. It is the only dedicated cancer center in The Netherlands and maintains an important role as a national and international center of scientific and clinical expertise, development and training.